No Prescription |
 |
 | ||
|
Desmopressin PH T Nasal Spray Generic Stimate |
|
| ||
No Prescription » Prescription Drugs 5 » Desmopressin PH T Nasal Spray Generic Stimate Desmopressin is used in people with certain bleeding problems (hemophilia A type 1 von Willebrand's disease) to control bleeding caused by surgery injuries or heavy menstrual periods. This medication is a man-made form of a certain substance in the body called vasopressin that helps with normal blood clotting.Indication:DESMOPRESSIN PH&T nasal spray solution is indicated for the treatment of cranial diabetes insipidus and for establishing renal concentration capacity testing.DESMOPRESSIN PH&T nasal spray solution is also indicated for the treatment of primary nocturnal enuresis in patients (from 5 years of age) with normal ability to concentrate urine.Dosage and Administration:1 dose of the spray provides 0.1ml which corresponds to 10Ág desmopressin acetate.Cranial diabetes insipidusDosage is individual after testing but normal dosage for adults is 10-20Ág 1-2 times daily. For children 5-10Ág 1-2 times daily. In the event of signs of water retention/hyponatremia treatment should be interrupted and the dose should be adjusted.Primary nocturnal enuresisA clinically effective dose is individual and may vary from 10 to 40Ág administered intranasally. A suitable initial dose is 20Ág intranasally at bedtime. Fluid restriction should be observed please see under Warnings and Precautions. In the event of signs of water retention/hyponatremia treatment should be interrupted. Assessment of the necessity of continued treatment should be made after three months during one substance-free week. Buy Desmopressin PH T Nasal Spray Generic Stimate and other Prescription Drugs 5 products online at Medstore. 5493
About Desmopressin PH T Nasal Spray Generic Stimate: Product Type: Prescription Drugs 5 Desmopressin PH&T Nasal Spray ( Generic Stimate ) Desmopressin PH&T Nasal Spray (Generic Stimate) Generic Stimate 0.1mg/mL 6mL Generic Stimate Desmopressin PH&T Nasal Spray
View more Prescription Drugs 5 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
